How Should Performance Verification Materials Be Prepared for Medical Device Registration in Thailand?

Key Summary

In short: To prepare performance verification materials for medical device registration in Thailand, a manufacturer should first confirm the product classification and the applicable registration pathway, and then prepare the technical file, labels and instructions for use (IFU), quality system evidence, authorization documents and local representative documentation. Existing NMPA documentation can be used as a basis, but it normally has to be adapted to Thai FDA (TFDA) requirements in terms of language, format, labeling and the evidence chain.

For Chinese medical device manufacturers, the more reliable approach is to complete a product classification and documentation gap assessment first, and then decide whether NMPA, CE, FDA, ISO 13485 or other market dossiers can be reused.

Thai registration usually affects the technical file, authorized representative, importer cooperation, label language, quality system evidence and subsequent change maintenance at the same time. If the project is driven only by the question of \"which documents to submit\", corrections or rework are likely to arise in model coverage, evidence chain consistency, labeling claims and certificate control.

AIMEILI recommends that companies plan this issue within a unified strategy for GHWP member states and multi-country market access, using one reusable core technical file to support localization in different markets instead of re-creating documentation for each country at short notice.

Companies should also make a project-based judgment by combining the latest requirements of the target country's regulatory authority, the existing technical file base, the product risk class and the launch plan, rather than mechanically preparing documents against a checklist.

This article has been compiled from AIMEILI's registration practice question bank, its medical device international registration knowledge base and publicly available regulatory information; specific projects should always be based on the latest requirements of the target country's regulatory authority and on the product documentation base.

Applicable Scenarios and Core Questions

Companies searching for \"how to prepare performance verification materials for medical device registration in Thailand\" are usually not looking for a conceptual explanation. What they really want to determine is whether their existing documentation can support a Thai submission, whether a local agent or authorized representative is needed, why the timeline may be extended, and which issues may affect the launch plan. Behind this question there are usually several factors at the same time: product classification, registration pathway, evidence chain, label localization and post-market maintenance responsibilities.

If a company plans to enter several GHWP member states or the Southeast Asian, Middle Eastern and Latin American markets at the same time, answering the process for a single country is not enough. A more valuable approach is to first turn the core technical file, quality system evidence, performance verification, clinical evidence, and labels and IFU into a reusable version, and then localize them according to each country's regulatory requirements.

Registration Assessment Logic

Companies should first confirm the intended use, mechanism of action, use scenario, mode of body contact, duration of use, whether the device is sterile, whether it is active, and whether it contains software or has IVD characteristics, and then determine the risk class and the submission pathway. Once the pathway is determined incorrectly, the translation, notarization, authorization, testing and supplementary documentation that follow will all go in the wrong direction.

For a Thai project, it is also necessary to confirm the applicant entity and the boundaries of local responsibility: who holds the certificate, who is responsible for regulatory communication, who handles import and post-market incidents, who triggers changes, and who maintains the renewal documentation. If these issues are left vague in a commercial contract only, market control can easily be affected later.

Documents and Evidence

Typical documentation includes the product description, model and specification matrix, intended use, risk classification rationale, ISO 13485 or applicable quality system evidence, technical file, performance verification reports, risk management file, clinical evaluation or clinical evidence, labels and IFU, authorization documents, existing registration certificates, manufacturer's declarations and post-market surveillance documentation.

The key to documentation quality is not quantity but consistency. IFU claims, the models covered by test reports, the applicable scope of clinical evidence, risk management conclusions, label warnings and the information in the registration application form must support each other. What regulators focus on is whether the device is safe, effective and traceable for the intended use, not whether the company has uploaded a large number of documents.

Common Mistakes

The most common problem is that companies treat registration as a simple document submission without first clarifying product classification, evidence coverage and local responsibility relationships.

• Submitting translations of domestic NMPA documents directly, without reorganizing the evidence according to the Thai pathway.
• Having too many models and specifications while the test reports, clinical evidence or labels do not cover them adequately.
• Selecting a local agent purely on the basis of a sales partnership, without clarifying regulatory responsibilities, certificate control and post-market maintenance obligations.
• Inconsistency between labels, IFU, promotional materials and registration claims, which leads to deficiency letters or post-market compliance risks.
• Failing to plan multi-country document reuse in advance, so that documentation is repeated for every country and both cost and timelines are inflated.

Company Preparation Checklist

Before starting a project, companies are advised to use an internal checklist to confirm the documentation base, so that critical evidence gaps are not discovered only after submission.

• Prepare a list of target products, a model and specification matrix, and intended use statements.
• Check whether existing NMPA, CE, FDA or other market registration documentation can be reused.
• Prepare the ISO 13485 certificate, test reports, risk management file, clinical evaluation and English IFU.
• Confirm the responsibilities, fees, certificate control and exit mechanism of the local agent or authorized representative.
• Establish a target-country gap assessment table that specifies what requires additional testing, translation, notarization or supplementary declarations.

AIMEILI Perspective

AIMEILI advises companies not to treat Thai registration as a one-off document submission, but to manage it as an overseas market access project. For companies preparing to enter multiple countries, building a clear core technical file and evidence matrix first and then converting it according to national requirements is usually faster, more stable and more conducive to subsequent changes and renewals than filling in documentation country by country at short notice.

From a project management perspective, there are three things companies should control in advance: first, product classification and pathway determination; second, the consistency of the documentation evidence chain; and third, the regulatory responsibility boundaries of local partners. As long as these three items remain unclear, a project may still face repeated rounds of deficiency responses, agent communication and post-market maintenance, even if the documentation appears substantial.

Common Follow-up Questions

Can domestic documentation be used directly for Thai registration?

Domestic documentation can serve as a basis, but it usually cannot be submitted as it is. Companies need to adapt the document structure, language, labels, authorization documents and evidence chain to local regulatory requirements.

When is the best time to start a gap assessment?

It is recommended to start immediately after confirming the target markets and the product list. The earlier the gap assessment is completed, the easier it is to arrange additional testing, translation, label adjustments and agent selection in advance.

Why does the choice of local agent affect registration quality?

The local agent usually takes part in registration communication, changes, renewals and post-market incident handling. Unclear rights and responsibilities will affect certificate control and subsequent market stability.

Quality System and Evidence Consistency

From a registration review perspective, quality system documentation is not an isolated certificate. Regulators usually examine whether the manufacturer's name, manufacturing site, product scope, certificate validity period, applicable standards and technical file are consistent with one another. If the scope covered by the ISO 13485 certificate does not match the products being submitted, or if the manufacturing address, model specifications and IFU version are inconsistent with the test reports, a company may still be asked for supplementary explanations even though it has prepared a large amount of documentation.

Before submission, companies should build an evidence consistency checklist that maps product names, model specifications, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, label and IFU versions and quality system certificates item by item. This may seem basic, but it can noticeably reduce the probability of deficiency letters, especially for projects submitted simultaneously to multiple GHWP member states or covering multiple product families.

Localization Conversion and Agent Responsibilities

Thai registration projects usually involve arrangements for a local agent, authorized representative, importer or registration holder. Companies need to confirm in advance whether the local partner is only responsible for submitting documentation, or whether it also handles regulatory communication, certificate maintenance, post-market incident reporting, change applications and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labels, IFU and authorization documents cannot simply be translated either. Companies should verify local language requirements, the boundaries of product claims, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information and after-sales contact details. For companies that already hold CE, FDA, NMPA or other market documentation, the focus of localization conversion is to transform reusable evidence into a submission structure acceptable in the target country, rather than writing an isolated set of documents from scratch.

Post-Market Maintenance and Long-Term Planning

Completing registration does not mean that compliance work is over. Companies also need to maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions and regulatory update records. Many companies invest heavily in obtaining the certificate but neglect post-market maintenance; once a manufacturing site change, model expansion, IFU update or agent replacement occurs, the certificate and market sales can easily become disconnected.

AIMEILI recommends managing this issue within an annual international registration plan: first clarify the priority of target markets, then build a reusable documentation package and a country-specific gap checklist, and finally schedule submission, deficiency responses, post-market maintenance and renewal milestones. The value of doing so lies not only in improving registration efficiency in a single country, but also in helping companies build a replicable overseas compliance capability and reducing the cost of starting documentation preparation from scratch every time they enter a new market.

Continue Reading

• Previous: What are the requirements for a risk management file for medical device registration in Thailand?
• Next: What should be done if quality system evidence for medical device registration in Thailand is inconsistent?

Recommended reading

• How should registration documentation for medical device registration in Malaysia be prepared?
• How is product classification determined for medical device registration in Malaysia?
• How should the technical file be organized for medical device registration in Malaysia?
• How should labels and IFU be localized for medical device registration in Malaysia?
• How should clinical evaluation documentation be prepared for medical device registration in Malaysia?
• Can test reports be reused for medical device registration in Malaysia?

Back to FAQ Center | News | Contact AIMEILI

Content Review and Applicability Scope

Author: AIMEILI Regulatory Editorial Team

Professional review: AIMEILI Medical Device International Registration Project Team

Source principle: Priority is given to official regulatory authorities, international organizations, standards organizations and publicly available regulatory materials; industry media and project experience are used only as supporting references for judgment.

Applicability scope: This article is intended for preliminary understanding, documentation preparation and project planning. It does not replace the formal requirements of the target country's regulatory authority, testing conclusions or legal advice.

Published: 10 July 2026, 13:52. Updated: 10 July 2026, 13:52.